Skip to content

Effect of Taoren Honghua Jian on Immune Function in Patients with Coronary Artery Disease

Effect of Taoren Honghua Jian on Immune Function in Patients with Stable Coronary Artery Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021772
Enrollment
Unknown
Registered
2019-03-08
Start date
2019-04-30
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable Coronary Artery Disease

Interventions

Experiment group:Taoren Honghua Jian
Control group:Taoren Honghua Jian placebo

Sponsors

Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria for chronic stable coronary heart disease: (1) Has a history of myocardial infarction, treated by or without revascularization (percutaneous coronary intervention or coronary artery bypass grafting); (2) Coronary angiography or coronary CT showed that the diameter of at least one main branch of the coronary artery is narrowed by more than 50%, and was treated with or without revascularization; 2. The type of TCM syndrome is Qi stagnant and blood stasis; 3. Patients aged 18-70 years; 4. Patients who volunteer to participate in the study and sign the informed consent; 5. no pregnancy or have no plans of pregnancy or feeding women.

Exclusion criteria

Exclusion criteria: (1) myocardial infarction (MI) and other heart disease, such as severe neurosis, menopausal syndrome, hyperthyroidism, chest pain caused by cervical spondylosis; (2) with severe hypertension, severe cardiopulmonary insufficiency, severe arrhythmia, immune system diseases; (3) allergic constitution or allergic to Taoren Honghua Jian or has serious adverse reactions; (4) tumor and cancer patients; (5) mania, depression and other mental disorders; (6) has a history of infectious diseases such as tuberculosis, hepatitis b and HIV virus and other infectious diseases; (7) poor control of internal diseases such as diabetes, hyperlipidemia, respiratory infections, etc.; (8) with opioid analgesic, sedative hypnotic drug and alcohol abuse history; (9) with severe liver and kidney disease or kidney function damage serious (ALT and AST more than 1.5 times higher than normal limit, serum creatinine level is higher than 1.5 times bigger than the upper limit of normal); (10) with blood system disease patients, such as 1) hemoglobin < 9 g/dL and hemoglobin and red blood cell press < 30%; 2) white blood cell count < 3.0 x 10^9/L; 3) neutrophil count < 1.2.0 x 10^9/L; 4) the platelet count < 100 x 10^9/L, etc.; (11) adherence is poor, cannot meet the requirement.

Design outcomes

Primary

MeasureTime frame
immune index;TCM syndrome score;

Secondary

MeasureTime frame
Single symptoms of TCM curative effect analysis;Seattle angina questionnaire;MOS Sleep Scale;ECG;echocardiography;

Countries

China

Contacts

Public ContactPing Liu

Longhua Hospital, Shanghai University of Traditional Chinese Medicine

wangyiruen@icloud.com+86 18917763029

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 18, 2026